Cargando…
Integration of Serum Metabolomics into Clinical Assessment to Improve Outcome Prediction of Metastatic Soft Tissue Sarcoma Patients Treated with Trabectedin
Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers with few diagnostic or prognostic biomarkers. This metabolomics study aimed to identify new serum prognostic biomarkers to improve the prediction of overall survival in patients with metastatic STS. The study enrolled 24 patien...
Autores principales: | Miolo, Gianmaria, Di Gregorio, Emanuela, Saorin, Asia, Lombardi, Davide, Scalone, Simona, Buonadonna, Angela, Steffan, Agostino, Corona, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409362/ https://www.ncbi.nlm.nih.gov/pubmed/32708128 http://dx.doi.org/10.3390/cancers12071983 |
Ejemplares similares
-
Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
por: Corona, Giuseppe, et al.
Publicado: (2023) -
Metabolic Clues to Bile Acid Patterns and Prolonged Survival in Patients with Metastatic Soft-Tissue Sarcoma Treated with Trabectedin
por: Miolo, Gianmaria, et al.
Publicado: (2023) -
Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas
por: Vignoli, Alessia, et al.
Publicado: (2023) -
Emerging Role of Metabolomics in Ovarian Cancer Diagnosis
por: Saorin, Asia, et al.
Publicado: (2020) -
The Riddle of Cetuximab-Related Skin Toxicity: (1)H-NMR Sebum Analysis Revealed Dynamic Lipid Alterations Associated with Skin Toxicity Development in Metastatic Colorectal Cancer Patients
por: Saorin, Asia, et al.
Publicado: (2022)